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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.07.063Objectives: Improvement in health-related quality of life is a major object of cardiac
surgery. However, high stress exposure during the perioperative period of cardiac
surgery can result in the formation of traumatic memories and symptoms of chronic
stress or even posttraumatic stress disorder, which can have negative effects on
health-related quality-of-life outcome. In this controlled study we examined whether
exogenously administered stress doses of hydrocortisone during cardiac surgery
reduce perioperative stress exposure and the long-term incidence of chronic stress
symptoms and improve health-related quality of life after cardiac surgery.
Methods: Thirty-six high-risk patients undergoing cardiac surgery were prospec-
tively randomized to receive either stress doses of hydrocortisone or placebo. Of 28
available patients at 6 months after cardiac surgery, 14 had received hydrocortisone,
and 14 had received placebo. Traumatic memories, chronic stress symptoms (post-
traumatic stress disorder scores), and health-related quality of life were measured by
using validated questionnaires.
Results: Compared with patients from the placebo group, patients from the hydro-
cortisone group had a significantly shorter duration of intensive care unit treatment,
required lower doses of the stress hormone norepinephrine during cardiac surgery,
and had significantly fewer stress symptoms and a better health-related quality of
life regarding physical function, chronic pain, general health, vitality, and mental
health during follow-up. The groups did not differ with regard to the number or type
of intensive care unit–related traumatic memories.
Conclusions: The use of stress doses of hydrocortisone in high-risk cardiac surgical
patients reduces perioperative stress exposure, decreases chronic stress symptoms,
and improves health-related quality of life at 6 months after cardiac surgery.
Cardiac surgery (CS) with cardiopulmonary bypass (CPB) improves health-related quality of life (HRQL) in the majority of patients.1 On the otherhand, consequences of CS also include a considerable risk for the develop-
ment of postoperative organ dysfunction, prolonged treatment in an intensive care
unit (ICU), and, in due course, a considerable risk of cognitive decline, which includes
deficits in verbal and visual memory, attention, and concentration.2 In addition, CS
represents a high stress exposure that is the combined result of critical illness, CPB, and
major operations; exogenously administered adrenergic stress hormones; and traumatic
experiences, such as pain, anxiety, or respiratory distress (particularly during ICU
treatment).3 There is increasing evidence that high perioperative stress exposure in
patients undergoing CS might result in chronic stress-related illness and even
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velopment of chronic stress symptoms or PTSD in patients
after CS is associated with a significant decrease in HRQL
outcomes, including impairments in physical function and
mental health,4 which might greatly reduce or even abolish
the benefits of CS.3,5
In addition to a characteristic pattern of emotional symp-
toms6 and the presence of traumatic memories from highly
aversive experiences,3,7 many patients with chronic stress-
related illness show distinct neuroendocrine abnormalities,
which include increased catecholaminergic activity and,
remarkably, a decreased activity of the hypothalamic-
pituitary-adrenocortical axis,6 which is reflected by a re-
duction in urinary cortisol excretion8 or systemic cortisol
levels.9 Interestingly, there is evidence from 2 recent studies
in patients with septic shock10 and after CS11 that prolonged
glucocorticoid administration (stress doses of hydrocorti-
sone12) during the actual stress exposure of ICU treatment
results in a decreased incidence and intensity of chronic
stress symptoms11 or PTSD10 during follow-up. The above-
mentioned 2 studies from our group did not investigate
other possible long-term consequences of stress doses of
hydrocortisone, however, namely a likely improvement in
HRQL outcomes that might include both physical and men-
tal aspects. We therefore conducted an additional study in
selected patients at high risk for perioperative complications
to address this important issue.
Patients and Methods
Between September 2002 and September 2003, we enrolled 36
high-risk patients in a prospective, randomized, double-blind trial.
All patients received a detailed explanation of the purpose of the
study and provided written informed consent. The study was
approved by the Institutional Review Board of the Ludwig-
Maximilians University of Munich, and data protection met the
standard set by German law.
Inclusion and Exclusion Criteria
The study was performed in high-risk patients undergoing CS with
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
CS  cardiac surgery
HRQL health-related quality of life
ICU  intensive care unit
IL-6  interleukin 6
POD  postoperative day
PTSD  posttraumatic stress disorder
SF-36  Short Form-36
TISS  Therapeutic Intervention Scoring SystemCPB. High risk was defined as a preoperative left ventricular
278 The Journal of Thoracic and Cardiovascular Surgery ● Febrejection fraction of less than 35% or an expected duration of CPB
of greater than 97 minutes.13 These criteria have been validated in
2 controlled studies by our group11,13 and showed that patients
who fulfilled these criteria required prolonged ICU treatment and
had an increased risk for a severe inflammatory reaction after CPB
and an increased incidence of chronic stress symptoms, which
were both responsive to stress doses of hydrocortisone. Patients
were excluded from the study if they met the following criteria
before surgical intervention: pregnancy, emergency operation, he-
patic dysfunction (bilirubin 3 mg/dL), renal dysfunction (plasma
creatinine 2 mg/dL), a positive serologic test result for HIV,
manifest insulin-dependent diabetes mellitus, an extracardial septic
focus, chronic or acute inflammatory disease, and inability to
provide informed consent. In addition, patients who required glu-
cocorticoids other than hydrocortisone were excluded.
Administration of Study Drugs
The patients were randomly assigned to one of 2 treatment groups
with the use of a computer-generated randomization list. One group of
patients received stress doses of hydrocortisone (Pharmacia & Up-
john, Erlangen, Germany; the hydrocortisone group),12 and pa-
tients from the other group (the placebo group) received normal
saline in identical vials in a double-blind fashion. The vials were
prepared by a study nurse who was not involved in the care of
patients participating in the trial.
Hydrocortisone administration started with a loading dose
(100 mg over 10 minutes administered intravenously) before in-
duction of anesthesia, followed by a continuous infusion of 10
mg/h for 24 hours (postoperative day [POD] 1), which was re-
duced to 5 mg/h on POD 2 and then tapered to 3  20 mg
administered intravenously on POD 3 and 3 10 mg administered
intravenously on POD 4.13
Measurements and Data Collection
Because of the established effects of catecholamines on stress
responses and stress-influenced memory formation,14 the duration
of administration and the maximal doses of the stress hormones
epinephrine (as an inotropic agent) and norepinephrine (to coun-
teract vasodilatatory hypotension) were registered. In addition,
perioperative data collection included the length of mechanical
ventilation, peak plasma concentration of lactic acid measured
during ICU therapy, serum levels of the proinflammatory cytokine
interleukin 6 (IL-6), the Simplified Acute Physiology Score during
the first 24 hours in the ICU, the Therapeutic Intervention Scoring
System (TISS) score daily during the stay in the ICU (Simplified
Acute Physiology Score and TISS scores were used as disease
severity indicators; for definition, see Table E1), and length of stay
in the ICU.
Evaluation of Study End Points
At 6 months after CS, the patients were contacted by telephone and
received a detailed re-explanation of the purpose of the study. In
particular, they were informed that we were interested in their
current quality of life, as well as their present state of physical and
mental health, without any direct referral to chronic stress symp-
toms or traumatic memories. After repeated oral consent, the
patients received questionnaires for evaluation of HRQL, trau-
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questionnaires were mailed back by the patients.
Instruments and Key Measures of the Study
End Points
HRQL. HRQL at 6 months after discharge from the ICU was
measured by using the self-administered Medical Outcomes Study
Short Form Survey that consists of 36 questions (SF-36). The
SF-36 covers 8 basic health concepts and has been widely used for
HRQL outcome evaluation of CS.15
Chronic stress symptoms and PTSD. The severity of stress
symptoms as they existed at 6 months after CS was measured with
a modified version of the Posttraumatic Stress Symptom 10 Ques-
tion Inventory (PTSS-10) questionnaire, which has been validated
in patients after ICU treatment.16 This instrument records the
presence and intensity of 10 stress symptoms: (1) sleep distur-
bance, (2) nightmares, (3) depression, (4) hyperalertness, (5) with-
drawal (emotional numbing and inability to care for others),
(6) generalized irritability, (7) frequent changes in mood, (8) guilt,
(9) fear and avoidance reactions with regard to the ICU, and (10)
increased muscle tension. Patients rated their symptoms on a scale
from 1 (never) to 7 (always). A summary score of more than 35 is
associated with a high probability of patients fulfilling the diag-
nostic criteria for PTSD.16
Evaluation of traumatic memories. All patients were asked to
complete a structured and validated questionnaire, evaluating dif-
ferent categories of traumatic memory from ICU therapy.16 For the
purpose of this study, a category of traumatic memory as measured
by the questionnaire was defined as the patients’ subjective recol-
lection of (1) respiratory distress-dyspnea, (2) feelings of anxiety-
panic, (3) pain, or (4) nightmares from the ICU.16 The patients
were asked to answer each of these 4 items “yes” or “no,” inde-
TABLE 1. Comparison of patient characteristics and treatm
placebo groups





Preoperative left ventricular ejection fraction (%)
Duration of CPB (min)*
Duration of aortic crossclamp (min)*
Duration of mechanical ventilation (h)*
Duration of ICU therapy (d)*
Length of hospital stay (d)*
Maximum epinephrine dosage (mg/h)*
Duration of epinephrine therapy (d)*
Maximum norepinephrine dosage (mg/h)*
Duration of norepinephrine therapy (d)*
Lactate (mmol/L)*‡
Interleukin 6 (pg/mL)*§
SAPS II, Simplified Acute Physiology Score; TISS, Therapeutic Intervention
are presented as medians (25th-75th percentiles). †Indicators of disease
intensive care unit treatment. §Measured at 48 hours after admittance topendent of the number of occasions the adverse experience oc-
The Journal of Thoracicurred. The number of items answered “yes” by a subject was
termed the number of categories of traumatic memory present.
In addition, when completing the questionnaire, patients were
asked to describe earlier and preexisting traumatic experiences (eg,
from the war) unrelated to CS and ICU therapy.
Statistics
Because in our previous studies neither stress symptoms nor SF-36
HRQL outcome scores were normally distributed,5,11 we intended
to use nonparametric tests. Continuous variables between the hy-
drocortisone and placebo groups were compared with the Mann-
Whitney U test. Discrete variables were compared with the 2 or
Fisher exact tests, where appropriate. Spearman rho was calculated
as a nonparametric measure of linear association between variables
(eg, the duration of ICU therapy and scores on the stress symptom
inventory). All statistical tests were of an exploratory nature.
Statistical calculations were performed with the SPSS 12.01 sta-
tistical package (SPSS Inc, Chicago, Ill). Results are expressed as
medians and 25th to 75th percentiles.
Results
Of the 36 patients enrolled in the study, 20 had undergone
coronary artery bypass grafting, 7 had undergone valve
operations, and 9 had undergone both procedures. From
these 36 patients, 30 returned questionnaires at 6 months
after CS; 2 of these patients had to be excluded from the
final analyses because of incomplete questionnaires (missing
data on traumatic memories and stress symptom scores). This
resulted in a final participation rate of 78% (28 patients). Five
of the excluded patients were from the hydrocortisone group,
data between patients from the hydrocortisone and
ne group (n  14) Placebo group (n  14) P value
4/14 5/14 1.0
(63-72) 69 (63-73) .68
(30-38) 36 (31-46) .51
(78-129) 234 (149-356) .01
(27-40) 30 (21-48) .98
(91-154) 112 (65-139) .64
(62-86) 85 (62-86) .85
(8-14) 14 (7-18) .53
(2-3) 6 (4-8) .01
(14-22) 18 (15-27) .17
(0.0-0.2) 0.0 (0.0-0.2) .60
(0.0-0.5) 0.0 (0.0-1.0) .20
(0.3-1.0) 0.8 (0.6-1.7) .02
(1.0-2.0) 4.0 (2.0-4.5) .01
(2-3.4) 2.6 (2-4.5) .47
(56-208) 309 (181-439) .05
ing System; CPB, cardiopulmonary bypass; ICU, intensive care unit. *Data



















seveand 3 were from the placebo group (P  .70, Fisher exact
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patient or treatment characteristics between included or
excluded patients (Table E1).
Demographic and Treatment Characteristics of the
Study Population
Patients from the hydrocortisone and placebo groups did not
differ with regard to the type of surgical procedures (data
not shown), age and sex distribution, or the duration of CPB
or aortic crossclamping (Table 1). Compared with patients
from the placebo group, however, patients who received
hydrocortisone had a significantly shorter postoperative stay
in the ICU, had significantly lower TISS scores, showed a
strong trend toward lower values of the proinflammatory
cytokine IL-6 (P  .05), and required significantly less
norepinephrine (both with regard to maximal dosage and
duration of administration, Table 1). When all 8 patients
with missing long-term outcome data were included in the
short-term outcome analyses, this had no effect on overall
short-term results; patients from the hydrocortisone
group still had significantly lower norepinephrine re-
quirements (regarding dosage and duration of exposure),
a significantly shorter duration of ICU stay (2 vs 6 days,
median values; P  .01), and significantly lower TISS
scores (Table E2).
HRQL Outcomes
At 6 months after CS, patients from the hydrocortisone
group had higher scores on 7 of 8 scales of the SF-36 that
comprised both physical and mental HRQL aspects, with
significant differences regarding physical function, pain,
general health perception, vitality, and emotional well-being
(Table 2) and no improvement regarding physical role func-
tion. Likewise, patients from the hydrocortisone group had
significantly higher SF-36 physical and mental summary
scores compared with those of patients from the placebo
group (Figure 1). When the 2 patients excluded from the
TABLE 2. Comparison of SF-36 HRQL scores at 6 months a
placebo groups
SF-36 items* Hydrocortisone group (n
Physical function 85 (49-90)
Physical role function 25 (0-75)
Pain† 100 (72-100)
General health perception 72 (65-75)
Vitality 58 (44-76)
Social function 88 (75-100)
Emotional role function 67 (17-100)
Mental health 80 (66-84)
SF-36, Short Form-36; HRQL, health-related quality of life; CS, cardiac surg
scores show a reverse coding (eg, higher scores indicate a lower pain instress symptom analyses because of missing data were
280 The Journal of Thoracic and Cardiovascular Surgery ● Febrincluded in the HRQL comparison, this did not significantly
change the results (data not shown).
Chronic Stress Symptoms and PTSD
Patients from the hydrocortisone group had significantly
lower chronic stress symptom scores when compared with
those of patients from the placebo group (median of 15.5
[interquartile range, 14.8-21.8] in the hydrocortisone group
vs median of 25.5 [interquartile range, 16.8-33.0] in the
control subjects, P. 03). Stress symptom scores correlated
positively with the duration of ICU therapy (Spearman
rho  0.38, P  .05). There were significant but not very
high correlations between stress symptom scores and SF-36
physical pain (rho  0.45, P  .02), vitality (rho 
0.48, P  .01), social function (rho  0.50, P  .01),
CS between patients from the hydrocortisone and









Data are presented as medians (25th-75th percentiles). †Note: SF-36 pain
ce and intensity).
Figure 1. Comparison of Short Form-36 health-related quality-of-
life summary scores between patients from the hydrocortisone
group (n  14, shaded box plots) and patients from the placebo
group (n 14, open box plots) measured at 6 months after cardiac
surgery. The whiskers at the top and bottom of each box indicate
the 5th and 95th percentiles of the distribution, respectively; the
top and bottom of each box indicate the 75th and 25th percentiles,
respectively; and the line through the box indicates the medianfter
 14
ery. *(the 50th percentile). *P < .03.
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summary scores (rho  0.60, P  .01).
Three of 14 patients from the placebo group and 1 of 14
patients from the hydrocortisone group showed evidence of
PTSD (as defined as a stress symptom score 35 points16).
Categories of Traumatic Memory
With regard to the total study population, 15 (53.6%) pa-
tients had potentially traumatic memories from the cardio-
vascular ICU, whereas 13 (46.4%) did not recall aversive
experiences. The most common category of traumatic mem-
ory from ICU treatment in the total study population was the
recall of respiratory distress in 6 (21.4%) patients, followed
by memories of pain in 5 (17.9%) patients, nightmares-
hallucinations in another 5 patients, and anxiety-panic in 3
(10.7%) individuals. Patients from the hydrocortisone and
placebo groups did not differ significantly with regard to the
number and type of traumatic memories (P  .33).
Twelve (42.9%) patients reported preexisting traumatic
memories unrelated to cardiovascular disease (mostly war
related). The number of patients with and without preexist-
ing traumatic memories did not differ between groups (P 
.70). Patients with preexisting traumatic memories demon-
strated an increased risk for traumatic memories from the
cardiovascular ICU (9/12 patients with preexisting trau-
matic memories also had at least one traumatic memory
from the ICU compared with 6/16 patients without prior
trauma, P  .07).
Discussion
This pilot study shows that stress doses of hydrocortisone
given to a predefined group of high-risk cardiac surgical
patients at induction of anesthesia and continued during
ICU treatment resulted in considerable short- and long-term
effects. Short-term advantages of stress doses of hydrocor-
tisone found in this study were a significant shortening of
the duration of ICU treatment, lower TISS scores, reduced
norepinephrine requirements, and a strong trend toward
lower concentrations of the proinflammatory cytokine IL-6.
These findings are in agreement with those of a previously
performed study in a comparable high-risk group of pa-
tients, which evaluated only the short-term benefits of stress
doses of hydrocortisone during CS.13
The long-term benefits of hydrocortisone treatment found in
this trial were a reduced incidence and intensity of chronic
stress symptoms and improvements in overall HRQL out-
comes. Importantly, these health benefits included improve-
ments in both mental and physical aspects of HRQL. In this
regard it is of interest to note that the occurrence of PTSD
symptoms in survivors of myocardial infarction signifi-
cantly increases the likelihood of cardiovascular readmis-
sion and a negative outcome.17 The inverse relationship
between the presence of chronic stress symptoms and
The Journal of ThoraciHRQL has been demonstrated in this study, as well as in
other patients after CS,3,5 critical illness requiring prolonged
ICU therapy,18,19 or other types of massive stressors.20
Whereas the negative relationship between the occurrence
of PTSD symptoms and mental health aspects of HRQL
appears to be conceivable, negative effects of chronic stress
symptoms on physical function in this and another study3
are more difficult to explain. One could speculate, however,
that patients with a high incidence and intensity of stress
symptoms are unable to appreciate possible physical bene-
fits of CS because stress symptoms might be perceived as
the constant presence of physical disease related to the
underlying coronary heart disease. In addition, the contin-
ued presence of stress symptoms could result in an increase
in allostatic load,21 changes in immune function, and non-
compliance with medication,17 which could all contribute to
adverse physical outcomes.
It is therefore likely that at least some of the long-term
effects of hydrocortisone on HRQL outcomes found in
this study are caused by a limitation and downregulation
of the original stress response triggered during the peri-
operative phase of CS.3 Increased stress exposure in pa-
tients from the placebo group might be reflected by higher
norepinephrine requirements found in this and another
study,13 although the number and type of traumatic memo-
ries (another important indicator of perioperative stress22)
did not differ between the groups.
Glucocorticoids have also been reported to directly affect
the recall of stored information. Some of the long-term
effects of hydrocortisone treatment on chronic stress symp-
toms (and likely HRQL) might have been mediated by these
well-established effects of glucocorticoids on mnemonic
processes.23 In this regard it is of interest to note that
patients found to have a low urinary cortisol excretion
immediately after a car accident had a higher incidence of
intrusive memories from the accident.24 Furthermore, long-
term survivors of the acute respiratory distress syndrome
with a high number of traumatic memories from ICU ther-
apy showed significantly lower serum cortisol levels, to-
gether with an increased incidence of chronic stress symp-
toms and risk for PTSD (unpublished data). Because it has
been proposed that PTSD symptoms develop over time after
trauma because of positive feedback mechanisms in which
the traumatic memories are constantly retrieved and re-
stored,25 low serum cortisol levels could facilitate repeated
recollections of the traumatic experiences, resulting in
strong intrusive memories and PTSD. A disruption of re-
trieval mechanisms in a close temporal relationship with a
traumatic experience caused by exogenously administered
hydrocortisone could theoretically result in a long-term
reduced incidence or intensity of PTSD symptoms.26 These
speculations are corroborated by findings from a pilot study
that prolonged administration of a very low dose of hydro-
c and Cardiovascular Surgery ● Volume 131, Number 2 281
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nonmedical origin resulted in a significant reduction of
traumatic memory retrieval.27
The issue of side effects from the treatment with hydro-
cortisone has not been addressed by this study because the
number of patients was too small to detect these effects.
However, Kilger and colleagues13 could demonstrate that
hydrocortisone, administered in the described way, does not go
along with relevant side effects, including acid-base disorders
and wound infections, in a larger cohort of patients.
In summary, our study indicates that the administration
of hydrocortisone in a dosage comparable with the endog-
enous maximal production rate during the perioperative
phase of CS is associated with a lower incidence of chronic
stress symptoms and an improvement in HRQL in selected
patients at high risk for perioperative complications. These
findings might have important implications regarding both
economic and pathophysiologic aspects of outcome in CS
but need to be confirmed in larger randomized trials.
We thank Dr James L. McGaugh for valuable comments on an
earlier version of the manuscript.
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Weis et al Cardiopulmonary Support and PhysiologyTABLE E1. Comparison of patient characteristics and treatment data between the final study population (included patients)
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be excluded because of incomplete questionnaires (n  2)
Patient and treatment data Included patients (n  28) Excluded patients (n  8) P value
Sex (F/M) 6/22 2/6 1.00
Age (y)* 69 (61-71) 68 (67-79) .38
SAPS II*† 36 (30-38) 38 (31-57) .40
TISS*‡ 116 (84-246) 145 (112-255) .64
Preoperative left ventricular ejection fraction (%) 30 (26-43) 32 (22-38) .82
Duration of CPB (min)* 117 (99-147) 105 (100-166) .17
Duration of aortic crossclamp (min)* 72 (60-105) 81 (77-112) .21
Duration of mechanical ventilation (h)* 11 (7-16) 12 (9-16) .67
Duration of ICU therapy (d)* 3 (2-4) 4 (2-6) .87
Length of hospital stay (d)* 17 (14-22) 16 (14-28) .84
Maximum epinephrine dosage (mg/h)* 0.0 (0.0-0.2) 0.1 (0.0-0.3) .38
Duration of epinephrine therapy (d)* 0.0 (0.0-0.5) 0.3 (0.0-1.0) .34
Maximum norepinephrine dosage (mg/h)* 0.6 (0.5-1.3) 0.9 (0.4-1.0) .75
Duration of norepinephrine therapy (d)* 1.8 (1.0-3.8) 2.5 (1.0-4.0) .67
Lactate (mmol/L)*§ 2.6 (1.8-3.9) 2.7 (2.2-6.6) .47
Interleukin 6 (pg/mL)* 169 (73-254) 309 (71-230) .57
CPB, Cardiopulmonary bypass; ICU, intensive care unit. *Data are presented as medians (25th-75th percentiles). †SAPS II (Simplified Acute Physiology
Score II) provides an estimate of the risk of death in the intensive care unit without having to specify a primary diagnosis and includes 17 variables: 12
physiology variables, age, type of admission (scheduled surgical, unscheduled surgical, or medical), and 3 underlying disease variables (AIDS, metastatic
cancer, and hematologic malignancy). The SAPS II has also been validated in patients from coronary care units. SAPS II was measured in the morning
of postoperative day 1. ‡TISS (Simplified Therapeutic Intervention Scoring System) provides an estimate of the time spent on nursing activities in a given
patient (1 TISS point is approximately equal to 11 minutes of nursing activities). §Peak concentration measured during intensive care unit treatment.
Measured at 48 hours after admittance to the intensive care unit.
TABLE E2. A comparison of patient characteristics and short-term outcomes between patients from the hydrocortisone and
placebo groups
Patient and treatment data Hydrocortisone group (n  19) Placebo group (n  17) P value
Sex (F/M) 4/15 4/13 .86
Age (y)* 68 (63-72) 69 (63-73) .69
SAPS II*† 34 (30-38) 36 (31-46) .51
TISS*‡ 99 (78-129) 234 (149-356) .01
Preoperative left ventricular ejection fraction (%) 30 (26-39) 31 (21-49) .84
Duration of CPB (min)* 98 (91-154) 112 (65-139) .64
Duration of aortic crossclamp (min)* 85 (43-113) 75 (62-86) .85
Duration of mechanical ventilation (h)* 11 (8-14) 14 (7-18) .53
Duration of ICU therapy (d)* 2 (2-3) 6 (4-8) .01
Length of hospital stay (d)* 15 (14-22) 18 (15-27) .19
Maximum norepinephrine dosage (mg/h)* 0.5 (0.3-1.0) 0.8 (0.6-1.7) .02
Duration of norepinephrine therapy (d)* 1.0 (1.0-2.0) 4.0 (2.0-4.5) .01
Lactate (mmol/L)*§ 2.3 (2.0-3.4) 2.6 (2.0-4.5) .47
Interleukin 6 (pg/mL)* 82 (56-207) 309 (181-440) .05
This comparison includes all originally randomized patients (n  36). CPB, Cardiopulmonary bypass; ICU, intensive care unit. *Data are presented as
medians (25th-75th percentiles). †The SAPS II (Simplified Acute Physiology Score II) provides an estimate of the risk of death in the intensive care unit
without having to specify a primary diagnosis and includes 17 variables: 12 physiology variables, age, type of admission (scheduled surgical, unscheduled
surgical, or medical), and 3 underlying disease variables (AIDS, metastatic cancer, and hematologic malignancy). The SAPS II has also been validated in
patients from coronary care units. SAPS II was measured in the morning of postoperative day 1. ‡TISS (Simplified Therapeutic Intervention Scoring System)
gives an estimate of the time spent on nursing activities in a given patient (1 TISS point is approximately equal to 11 minutes of nursing activities). §Peak
concentration measured during intensive care unit treatment. Measured at 48 hours after admittance to the intensive care unit.
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